Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 370
- Registration Number
- NCT00003375
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 500
- Registration Number
- NCT00052455
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
- Conditions
- Brain TumorsCentral Nervous System Tumors
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 428
- Registration Number
- NCT00002944
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00049439
- Locations
- 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇰🇪University of Nairobi College of Health Sciences, Nairobi, Kenya
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Colorado Health Foundation
- Target Recruit Count
- 270
- Registration Number
- NCT00003788
- Locations
- 🇨🇦
St. Michael's Hospital-Annex, Toronto, Ontario, Canada
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Rocky Mountain Neurological Associates, Englewood, Colorado, United States
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 230
- Registration Number
- NCT00004259
- Locations
- 🇺🇸
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton, Marlton, New Jersey, United States
🇺🇸Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees, New Jersey, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Riverside Haematology Group
- Target Recruit Count
- 660
- Registration Number
- NCT00003603
- Locations
- 🇬🇧
Hammersmith Hospital, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.